Patents by Inventor Jane Sanders
Jane Sanders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240043498Abstract: A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity.Type: ApplicationFiled: June 16, 2023Publication date: February 8, 2024Inventors: Bernard REES SMITH, Jadwiga FURMANIAK, Jane SANDERS, Jennifer MILLER-GALLACHER
-
Patent number: 11732026Abstract: A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity.Type: GrantFiled: June 11, 2015Date of Patent: August 22, 2023Assignee: RSR LimitedInventors: Bernard Rees Smith, Jadwiga Furmaniak, Jane Sanders, Jennifer Miller-Gallacher
-
Patent number: 10428153Abstract: According to one aspect there is provided An isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR.Type: GrantFiled: July 2, 2015Date of Patent: October 1, 2019Assignee: RSR Ltd.Inventors: Bernard Rees-Smith, Jane Sanders, Jadwiga Furmaniak
-
Publication number: 20170204159Abstract: A mutant thyroid stimulating hormone receptor (TSHR) or fragment thereof comprises one or more mutations, wherein the mutant TSHR has increased thermostability with respect to the equivalent wild type TSHR or fragment. The one or more mutation is preferably within the extracellular leucine-rich repeat domain (LRD) of the TSHR, or within residues 22 to 260 (TSHR260) of the TSHR, or may be in the transmembrane domain (TMD), A mutant TSHR or fragment thereof of the invention preferably consists of, or consists essentially of, the subdomain TSHR260 of the TSHR receptor. A mutant TSHR or fragment thereof according to the invention has a greater thermostability than the equivalent wild type TSHR or fragment as determined by its half-life at a given temperature, and can be purified whilst retaining activity. A mutant TSHR or fragment thereof according to the invention may also be deglycosylated whilst retaining activity.Type: ApplicationFiled: June 11, 2015Publication date: July 20, 2017Inventors: Bernard REES SMITH, Jadwiga FURMANIAK, Jane SANDERS, Jennifer MILLER-GALLACHER
-
Publication number: 20150344582Abstract: According to one aspect there is provided An isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR.Type: ApplicationFiled: July 2, 2015Publication date: December 3, 2015Inventors: Bernard Rees-Smith, Jane Sanders, Jadwiga Furmani-AK
-
Patent number: 9147036Abstract: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: GrantFiled: July 24, 2013Date of Patent: September 29, 2015Assignee: RSR LIMITEDInventors: Jane Sanders, Jadwiga Furmaniak, Barnard Rees Smith
-
Patent number: 9073992Abstract: According to one aspect there is provided an isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity, wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR.Type: GrantFiled: December 23, 2009Date of Patent: July 7, 2015Assignee: RSR Ltd.Inventors: Bernard Rees-Smith, Jane Sanders, Jadwiga Furmaniak
-
Patent number: 9046519Abstract: A mutated TSHR preparation which includes at least one point mutation characterized in that at least amino acid Arg at a position corresponding to amino acid 255 of a full length human TSHR has been mutated to a different amino acid residue in said mutated TSHR preparation, whereby said mutated TSHR preparation differentially interacts with patient serum stimulating TSHR autoantibodies, patient serum blocking TSHR autoantibodies and TSH, in that (i) the stimulatory effect of patient serum stimulating TSHR autoantibodies interacting with the mutated TSHR preparation is substantially reduced or essentially abolished, when compared to the stimulatory effect of the patient serum stimulating TSHR autoantibodies interacting with a reference TSHR preparation which has an amino acid sequence corresponding to that of said mutated TSHR preparation with the exception that said mutation of Arg at a position corresponding to amino acid 255 of a full length human TSHR is not present in said reference TSHR preparation, (ii)Type: GrantFiled: August 3, 2005Date of Patent: June 2, 2015Assignee: RSR LimitedInventors: Bernard Rees Smith, Jadwiga Furmaniak, Jane Sanders
-
Patent number: 8900823Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: GrantFiled: December 29, 2011Date of Patent: December 2, 2014Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Patent number: 8840891Abstract: The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.Type: GrantFiled: February 14, 2008Date of Patent: September 23, 2014Assignee: RSR LimitedInventors: Bernard Rees Smith, Jadwiga Furmaniak, Jane Sanders
-
Patent number: 8753637Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: GrantFiled: December 28, 2011Date of Patent: June 17, 2014Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Publication number: 20140074448Abstract: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: ApplicationFiled: July 24, 2013Publication date: March 13, 2014Applicant: RSR LIMITEDInventors: Jane SANDERS, Jadwiga FURMANIAK, Barnard Rees SMITH
-
Publication number: 20130183313Abstract: The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.Type: ApplicationFiled: February 14, 2008Publication date: July 18, 2013Applicant: RSR LIMITEDInventors: Bernard Rees Smith, Jadwiga Furmaniak, Jane Sanders
-
Publication number: 20130059317Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: ApplicationFiled: December 29, 2011Publication date: March 7, 2013Applicant: RSR LIMITEDInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Publication number: 20120276117Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: ApplicationFiled: December 28, 2011Publication date: November 1, 2012Applicant: RSR LIMITEDInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Publication number: 20120087911Abstract: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: ApplicationFiled: November 29, 2011Publication date: April 12, 2012Applicant: RSR LIMITEDInventors: JANE SANDERS, JADWIGA FURMANIAK, BARNARD REES SMITH
-
Patent number: 8110664Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: GrantFiled: November 28, 2003Date of Patent: February 7, 2012Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Patent number: 8097699Abstract: This invention relates to a crystallizable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: GrantFiled: August 29, 2007Date of Patent: January 17, 2012Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Publication number: 20110300138Abstract: According to one aspect there is provided an isolated human antibody molecule which binds to the TSHR and which reduces ligand-induced stimulation of the TSHR but has no effect on TSHR constitutive activity, wherein the isolated human antibody molecule has the characteristic of patient serum TSHR autoantibodies of inhibiting TSH and M22 binding to the TSHR.Type: ApplicationFiled: December 23, 2009Publication date: December 8, 2011Inventors: Bernard Rees-Smith, Jane Sanders, Jadwiga Furmaniak
-
Publication number: 20100233189Abstract: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: ApplicationFiled: August 29, 2007Publication date: September 16, 2010Inventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith